Bajaj Healthcare has announced the launch of Magnesium L- Threonate, a nutritional supplement used to normalize magnesium level in the body and helps to improve memory, muscle and nerve function and also aids in brain development by reversing the brain aging. It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease etc. It is available in capsule form.

Among the advantages of the Magnesium L-Threonate, is that it is used to prevent the loss of synapses and to improve the cognitive functions of the brain. It increases the magnesium ion concentration in the brain better than Magnesium Sulphate and it helps to improve long term and short-term memory loss.
It has an addressable market size is approximately INR 1500 million.

Commenting on the launch Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to add Magnesium L-Threonate to our growing product portfolio and continue to carry through Bajaj's commitment to deliver therapeutical products every year.

BHL intend to produce 12-15 tons of Magnesium L-Threonate in Q4 FY22 and 120 tons in FY23. We are expecting notable sales coming from the product. Addition of this new product in our existing product portfolio will further fuel the growth strategy for our formulation business. Addition of Magnesium LThreonate in our existing portfolio will further fuel the growth of our business and strengthen our position in the market."